Acceleron Pharma Inc.
ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF

Last updated:

Abstract:

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

Status:
Application
Type:

Utility

Filling date:

8 Feb 2022

Issue date:

4 Aug 2022